These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23218778)

  • 21. N-(3,4-Dimethylisoxazol-5-yl)piperazine-4-[4-(2-fluoro-4-[(11)C]methylphenyl)thiazol-2-yl]-1-carboxamide: A promising positron emission tomography ligand for fatty acid amide hydrolase.
    Shimoda Y; Fujinaga M; Hatori A; Yui J; Zhang Y; Nengaki N; Kurihara Y; Yamasaki T; Xie L; Kumata K; Ishii H; Zhang MR
    Bioorg Med Chem; 2016 Feb; 24(4):627-34. PubMed ID: 26740152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
    Myllymäki MJ; Saario SM; Kataja AO; Castillo-Melendez JA; Nevalainen T; Juvonen RO; Järvinen T; Koskinen AM
    J Med Chem; 2007 Aug; 50(17):4236-42. PubMed ID: 17665899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM; Jones WM; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz MJ; Scott BP; Wilson SJ; Luo L; Wennerholm ML; Chang L; Brown SM; Rizzolio M; Rynberg R; Chaplan SR; Breitenbucher JG
    Bioorg Med Chem Lett; 2014 Feb; 24(3):737-41. PubMed ID: 24433863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
    Morera L; Labar G; Ortar G; Lambert DM
    Bioorg Med Chem; 2012 Nov; 20(21):6260-75. PubMed ID: 23036333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
    Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
    J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
    Roughley SD; Browne H; Macias AT; Benwell K; Brooks T; D'Alessandro J; Daniels Z; Dugdale S; Francis G; Gibbons B; Hart T; Haymes T; Kennett G; Lightowler S; Matassova N; Mansell H; Merrett A; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Simmonite H; Tan K; Walls SB; Wong M
    Bioorg Med Chem Lett; 2012 Jan; 22(2):901-6. PubMed ID: 22209458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds as dual inhibitors of human cytosolic phospholipase A2α and fatty acid amide hydrolase.
    Zahov S; Drews A; Hess M; Schulze Elfringhoff A; Lehr M
    ChemMedChem; 2011 Mar; 6(3):544-9. PubMed ID: 21259444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields.
    Myllymäki MJ; Käsnänen H; Kataja AO; Lahtela-Kakkonen M; Saario SM; Poso A; Koskinen AM
    Eur J Med Chem; 2009 Oct; 44(10):4179-91. PubMed ID: 19539407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase.
    De Simone A; Russo D; Ruda GF; Micoli A; Ferraro M; Di Martino RM; Ottonello G; Summa M; Armirotti A; Bandiera T; Cavalli A; Bottegoni G
    J Med Chem; 2017 Mar; 60(6):2287-2304. PubMed ID: 28182408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, microwave-assisted synthesis, biological evaluation and molecular modeling studies of 4-phenylthiazoles as potent fatty acid amide hydrolase inhibitors.
    Wilt SR; Rodriguez M; Le TNH; Baltodano EV; Salas A; Pecic S
    Chem Biol Drug Des; 2020 May; 95(5):534-547. PubMed ID: 32061147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM; Jones W; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz M; Scott BP; Wilson SJ; Luo L; Wennerholm M; Chang L; Rizzolio M; Rynberg R; Chaplan S; Guy Breitenbucher J
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127463. PubMed ID: 32784090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
    Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Walker MC; Schweitzer BA; Madsen HM; Tenbrink RE; McDonald J; Smith SE; Foltin S; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6538-44. PubMed ID: 21924614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system.
    Gattinoni S; De Simone C; Dallavalle S; Fezza F; Nannei R; Amadio D; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
    ChemMedChem; 2010 Mar; 5(3):357-60. PubMed ID: 20112328
    [No Abstract]   [Full Text] [Related]  

  • 34. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
    Hart T; Macias AT; Benwell K; Brooks T; D'Alessandro J; Dokurno P; Francis G; Gibbons B; Haymes T; Kennett G; Lightowler S; Mansell H; Matassova N; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Walls S; Wong M; Roughley S
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4241-4. PubMed ID: 19515560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
    Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase.
    Forster L; Ludwig J; Kaptur M; Bovens S; Elfringhoff AS; Holtfrerich A; Lehr M
    Bioorg Med Chem; 2010 Jan; 18(2):945-52. PubMed ID: 20005725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1-Heteroaryl-3-phenoxypropan-2-ones as inhibitors of cytosolic phospholipase A₂α and fatty acid amide hydrolase: Effect of the replacement of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability.
    Sundermann T; Fabian J; Hanekamp W; Lehr M
    Bioorg Med Chem; 2015 May; 23(10):2579-92. PubMed ID: 25862211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
    J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
    Minkkilä A; Saario SM; Käsnänen H; Leppänen J; Poso A; Nevalainen T
    J Med Chem; 2008 Nov; 51(22):7057-60. PubMed ID: 18983140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies.
    Käsnänen H; Myllymäki MJ; Minkkilä A; Kataja AO; Saario SM; Nevalainen T; Koskinen AM; Poso A
    ChemMedChem; 2010 Feb; 5(2):213-31. PubMed ID: 20024981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.